Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Ko AH, et al. Among authors: siveke jt. Oncologist. 2023 Jun 2;28(6):553-e472. doi: 10.1093/oncolo/oyad022. Oncologist. 2023. PMID: 36940261 Free PMC article. Clinical Trial.
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I, Treckmann JW, Prasnikar N, Linden G, Markus P, Schumacher B, Albers D, Herold T, Ting S, Schmidt H, Radunz S, Wiesweg M, Siveke J, Schuler M, Kasper S. Virchow I, et al. Oncol Res Treat. 2023;46(3):89-99. doi: 10.1159/000529012. Epub 2023 Jan 9. Oncol Res Treat. 2023. PMID: 36623497 Clinical Trial.
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
Zogopoulos G, Haimi I, Sanoba SA, Everett JN, Wang Y, Katona BW, Farrell JJ, Grossberg AJ, Paiella S, Klute KA, Bi Y, Wallace MB, Kwon RS, Stoffel EM, Wadlow RC, Sussman DA, Merchant NB, Permuth JB, Golan T, Raitses-Gurevich M, Lowy AM, Liau J, Jeter JM, Lindberg JM, Chung DC, Earl J, Brentnall TA, Schrader KA, Kaul V, Huang C, Chandarana H, Smerdon C, Graff JJ, Kastrinos F, Kupfer SS, Lucas AL, Sears RC, Brand RE, Parmigiani G, Simeone DM; PRECEDE Consortium. Zogopoulos G, et al. J Natl Compr Canc Netw. 2024 Apr;22(3):158-166. doi: 10.6004/jnccn.2023.7097. J Natl Compr Canc Netw. 2024. PMID: 38626807
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J, Kasper S, Treckmann JW, Markus P, Schumacher B, Albers D, Wendling J, Ting S, Mende B, Maßmann M, Markus M, Virchow I, Rosery V, Laue K, Zaun G, Kostbade K, Pogorzelski M, Reissig TM, Liffers ST, Schmid K, Schildhaus HU, Schuler M, Siveke JT, Wiesweg M. Roehrle J, et al. Among authors: siveke jt. Oncol Res Treat. 2023;46(4):140-150. doi: 10.1159/000529452. Epub 2023 Jan 31. Oncol Res Treat. 2023. PMID: 36720216
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].
Hartlapp I, Valta-Seufzer D, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens UM, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Anger F, Germer CT, Stang A, Kimmel B, Heinemann V, Kunzmann V; German Pancreatic Cancer Group (AIO-PAK) and NEOLAP investigators. Hartlapp I, et al. Among authors: siveke jt. ESMO Open. 2024 May 3;9(5):103463. doi: 10.1016/j.esmoop.2024.103463. Online ahead of print. ESMO Open. 2024. PMID: 38703429 No abstract available.
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, Boeck S, Haas M. Weiss L, et al. Among authors: siveke jt. ESMO Open. 2024 Apr;9(4):102944. doi: 10.1016/j.esmoop.2024.102944. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503144 Free PMC article.
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, Lanzafame H, Kasper S, Nader M, Kesch C, von Tresckow B, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: siveke jt. J Nucl Med. 2024 Feb 8:jnumed.123.266652. doi: 10.2967/jnumed.123.266652. Online ahead of print. J Nucl Med. 2024. PMID: 38331453
Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
Godfrey LK, Forster J, Liffers ST, Schröder C, Köster J, Henschel L, Ludwig KU, Lähnemann D, Trajkovic-Arsic M, Behrens D, Scarpa A, Lawlor RT, Witzke KE, Sitek B, Johnsen SA, Rahmann S, Horsthemke B, Zeschnigk M, Siveke JT. Godfrey LK, et al. Among authors: siveke jt. Clin Epigenetics. 2024 Jan 16;16(1):13. doi: 10.1186/s13148-024-01623-z. Clin Epigenetics. 2024. PMID: 38229153 Free PMC article.
192 results